雑誌文献を検索します。書籍を検索する際には「書籍検索」を選択してください。

検索

書誌情報 詳細検索 by 医中誌

Japanese

Fabry Disease in Light of Recent Review Eiichiro Uyama 1 1Department of Neurology,Kumamoto Takumadai Hospital Keyword: Fabry disease , α-galactosidase A , globotriaosylceramide cerebral infarction , dolichoectasia , enzyme replacement therapy pp.1235-1244
Published Date 2008/11/1
DOI https://doi.org/10.11477/mf.1416100372
  • Abstract
  • Look Inside
  • Reference

Abstract

 Fabry disease is a lysosomal storage disorder that is caused by mutations in the gene encoding α-galactosidase A on Xq22.1. Typically hemizygous male patients exhibit classic phenotypes such as angiokeratoma,acroparesthesias,episodic pain "crises," hypohidrosis,and whorl-shaped corneal opacities from childhood. However,during adulthood,they gradually develop kidney failure,heart disease,and strokes resulting in early death between 40 to 50 years of age. However,recent studies have indicated a high prevalence of disabling clinical symptoms in heterozygous females patients. Patients having the cardiac variant of Fabry's disease exhibit only left ventricular hypertrophy,while patients having the renal variant exhibit only kidney failure. Individuals affected by these variants show higher residual enzyme activity of α-galactosidase A than individuals affected by the classic form of Fabry's disease due to missense mutations of the GLA gene.

 The cerebrovascular involvement in Fabry disease is not rare in both adult hemizygotes and heterozygotes. Infarctions caused by the occulsion of small vessels involving mostly the vertebrobasilar region in approximately two-thirds of the cases,and that is associated with the deposition glycoshingolipids including GL-3 in the walls of these vessels. In Caucasian patients,elongated,ectatic,and tortuous vertebral and basilar arteries are frequently observed on MRAs. Life-threatening megadolichobasilar anomaly with thrombosis has been identified in a large Hungarian family in which the family members share L16P mutation. On performing MRI,an increased signal intensity was observed in the pulvinar in T1-weighted images; this is the characteristic so-called "pulvinar sign".

 Enzyme replacement therapy has been approved in Japan since 2004 and 2007 for agalsidase β and agalsidase α,respectively. This treatment modestly improves the small-fiber neuropathy,hypohidrosis,hypertrophic cardiomyopathy,and stabilizes the renal function in the long term for up to 54 months. However,it has not helped in decreasing the incidence of strokes.


Copyright © 2008, Igaku-Shoin Ltd. All rights reserved.

基本情報

電子版ISSN 1344-8129 印刷版ISSN 1881-6096 医学書院

関連文献

  • Fabry病の診断 土井 研人 南江堂 臨床雑誌内科
    115巻 6号 (2015年6月)
    pp.1040
    • 有料閲覧
  • 28.Fabry病 小林 正久 東京医学社 小児内科
    54巻 13号 (2022年12月)
    pp.191-195
    • 有料閲覧
  • Fabry病 鶴留 康弘 , 寺崎 浩子 医学書院 臨床眼科
    67巻 5号 (2013年5月)
    pp.653
    • 有料閲覧
  • Fabry病 米澤 久司 南江堂 臨床雑誌内科
    123巻 6号 (2019年6月)
    pp.1285-1288
    • 有料閲覧
  • Fabry病 金澤 一郎 , 宮武 正 医学書院 Brain and Nerve 脳と神経
    25巻 8号 (1973年8月)
    pp.983-986
    • 有料閲覧
もっと見る

文献を共有